Corbus Pharmaceuticals Holdings (CRBP) Non-Current Debt (2013 - 2024)

Corbus Pharmaceuticals Holdings' Non-Current Debt history runs 6 years deep, the most recent figure standing at $10.7 million for Q2 2024.

• On a quarterly basis, Non-Current Debt fell 5.08% year-over-year to $10.7 million in Q2 2024; TTM through Jun 2024 was $10.7 million, a 5.08% decrease from a year earlier, with the FY2023 full-year figure at $15.9 million, changed 0.48% from the prior year.
• Non-Current Debt slipped to $10.7 million in Q2 2024 per CRBP's latest filing, from $15.9 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $18.6 million in Q3 2021 and bottomed at $9.4 million in Q3 2022.
• The 5-year median for Non-Current Debt is $15.8 million (2021), against an average of $14.9 million.
• Across the five-year window, Non-Current Debt grew 3.89% in 2021 and tumbled 49.4% in 2022, its largest moves.
• Year by year, Non-Current Debt stood at $18.0 million in 2020, then dropped by 13.27% to $15.6 million in 2021, then gained by 2.23% to $16.0 million in 2022, then declined by 0.48% to $15.9 million in 2023, then tumbled by 32.46% to $10.7 million in 2024.
• Per Business Quant, the three latest CRBP Non-Current Debt figures stand at $10.7 million (Q2 2024), $15.9 million (Q4 2023), and $11.3 million (Q2 2023).